These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2116582)

  • 1. Economic assessments in randomized controlled trials.
    Bulpitt CJ; Fletcher AE
    Med J Aust; 1990 Aug; 153(S1):S16-9. PubMed ID: 2116582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring costs and financial benefits in randomized controlled trials.
    Bulpitt CJ; Fletcher AE
    Am Heart J; 1990 Mar; 119(3 Pt 2):766-70; discussion 770-1. PubMed ID: 2106770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles involved in costing.
    Evans DB
    Med J Aust; 1990 Aug; 153(S1):S10-2. PubMed ID: 2116580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What every doctor should know about economics. Part 1. The benefits of costing.
    Hall J; Mooney G
    Med J Aust; 1990 Jan; 152(1):29-31. PubMed ID: 2104645
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
    Avorn J; Benner J; Ford I; Ganz DA; Gaw A; Glynn RJ; Jackson J; Lagaay AM; Schneeweiss S; Walley T; Wang PS;
    Control Clin Trials; 2002 Dec; 23(6):757-73. PubMed ID: 12505250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailored, Therapist-Guided Internet-Based Cognitive Behavioral Therapy Compared to Care as Usual for Patients With Rheumatoid Arthritis: Economic Evaluation of a Randomized Controlled Trial.
    Ferwerda M; van Beugen S; van Middendorp H; Visser H; Vonkeman H; Creemers M; van Riel P; Kievit W; Evers A
    J Med Internet Res; 2018 Oct; 20(10):e260. PubMed ID: 30309835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):395-420. PubMed ID: 15853438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal.
    Kawachi I; Malcolm LA
    J Hypertens; 1991 Mar; 9(3):199-208. PubMed ID: 1851782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
    Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
    Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
    Tavakoli M; Malek M
    J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD.
    Marseille E; Kahn JG; Yazar-Klosinski B; Doblin R
    PLoS One; 2020; 15(10):e0239997. PubMed ID: 33052965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles of cost-effective resource allocation in health care organizations.
    Weinstein MC
    Int J Technol Assess Health Care; 1990; 6(1):93-103. PubMed ID: 2113893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
    van den Hout WB; Kramer GW; Noordijk EM; Leer JW
    J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.